Bristol Myers Squibb Presents New Clinical and Real-World Data on Mavacamten and Obstructive Hypertrophic Cardiomyopathy at Upcoming American College of Cardiology?s 70th?Annual Scientific Se
New analysis of EXPLORER-HCM trial assessing impact of mavacamten on patient?s health status to be presented as late-breaking oral presentation
Interim results of EXPLORER long-term extension study of mavacamten safety and efficacy data in patients with obstructive hypertrophic cardiomyopathy (oHCM)?also to be presented
PRINCETON, N.J.--(BUSINESS WIRE)--Bristol Myers Squibb?(NYSE: BMY) today announced that data from multiple studies across the company?s clinical program investigating mavacamten in patients with obstructive hypertrophic cardiomyopathy (oHCM) will be presented at the upcoming American College of Cardiology?s 70th?Annual Scientific Session (ACC.21), being held virtually May 15 to May 17, 2021.
Key presentations include:$BMY to present new clinical and real-world data in obstructive hypertrophic cardiomyopathy at #ACC21
Tweet this
- A late-breaking oral presentation reporting results from a new analysis of data from the EXPLORER-HCM Phase 3 trial of mavacamten in patients with oHCM, which tested the impact of mavacamten on patients? health status (symptoms, function and quality of life) as measured by the Kansas City Cardiomyopathy Questionnaire. These data will be presented as part of the Featured Clinical Research I Session in the Hot Topics Channel on Saturday, May 15 from 12:15 ? 1:30 p.m. EDT.
- A moderated poster session highlighting interim results from MAVA-LTE, an ongoing, dose-blinded 5-year extension study of the EXPLORER-HCM Phase 3 trial. Findings from the interim analysis demonstrated that in patients with oHCM, mavacamten was well tolerated and showed durable improvement in left ventricular outflow tract (LVOT) gradients, diastolic function, N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and symptoms.
- A poster presentation of results from a real-world data analysis measuring the clinical and economic burden of oHCM in the United States, which found the condition is associated with substantial healthcare resource utilization and costs.
- Health Status Benefits of Mavacamten in Patients with Symptomatic Obstructive Cardiomyopathy: Results From the EXPLORER-HCM Randomized Clinical Trial
- Author: John A. Spertus
- Session 403-09 ? Featured Clinical Research I
- Session Type: Late-Breaking Clinical Trials, Hot Topics Channel
- Saturday, May 15: 12:15 ? 12:25 p.m. EDT
- Long-Term Safety of Mavacamten in Patients with Obstructive Hypertrophic Cardiomyopathy: Interim Results of the MAVA-Long Term Extension (LTE) Story
- Author: Florian Rader
- Session 1033-03 ? Advances in Hypertrophic Cardiomyopathy
- Session Type: Moderated Poster Contributions, eAbstract Site
- Saturday, May 15: 12:30 ? 12:40 p.m. EDT
- Clinical and Economic Burden of Obstructive Hypertrophic Cardiomyopathy in the United States
- Author: Sneha S. Jain
- Session 2192 ? Heart Failure and Cardiomyopathies: Population Science 1
- Session Type: Poster Contributions, eAbstract Site
- Saturday, May 15: 2:45 ? 3:30 p.m. EDT